Stelara Approval Expands; Good News in Celiac Disease; Curcumin for Adenomas

(MedPage Today) -- The FDA said it expanded approval of the interleukin (IL)-12/23 antagonist ustekinumab (Stelara) to include treatment of moderately to severely active ulcerative colitis in children as young as 2 years. Using pooled data from...

Read it at MedPage Today ↗

← Front page